Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

计划入组 14 人 · 首次发布于 2014 年 10 月 28 日

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

计划入组 43 人 · 首次发布于 2018 年 8 月 29 日

Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

计划入组 10 人 · 首次发布于 2020 年 4 月 24 日

NUCC-0227383

EBV-specific TCR-T cells (nasopharyngeal carcinoma/ metastatic head and neck carcinoma)

Head and Neck Cancer(Diakonos)

Danish Head And Neck Cancer Group

CELL AND GENE THERAPY CATAPULT

United Kingdom

INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE

India

PDS Biotech Presents Promising VERSATILE-002 Data for HPV16-Positive Head and Neck Cancer

BioNTech's BNT113 mRNA Cancer Vaccine Advances in Phase 2 Trial for HPV+ Head and Neck Cancer

Bicara Launches Pivotal Phase 2/3 Trial of Novel Bifunctional Antibody for Advanced Head and Neck Cancer